Rationale: Macrophage migration inhibitory factor (MIF) is released on platelet activation. Circulating MIF could potentially regulate platelets and thereby platelet-mediated inflammatory and regenerative mechanisms. However, the effect of MIF on platelets is unknown. Objective: The present study evaluated MIF in regulating platelet survival and thrombotic potential. Methods and Results: MIF interacted with CXCR4-CXCR7 on platelets, defining CXCR7 as a hitherto unrecognized receptor for MIF on platelets. MIF internalized CXCR4, but unlike CXCL12 (SDF-1α), it did not phosphorylate Erk1/2 after CXCR4 ligation because of the lack of CD74 and failed in subsequent CXCR7 externalization. MIF did not alter the activation status of platelets. However, MIF rescued platelets from activation and BH3 mimetic ABT-737-induced apoptosis in vitro via CXCR7 and enhanced circulating platelet survival when administered in vivo. The antiapoptotic effect of MIF was absent in Cxcr7 −/− murine embryonic cells but pronounced in CXCR7transfected Madin-Darby canine kidney cells. This prosurvival effect was attributed to the MIF-CXCR7-initiated PI3K-Akt pathway. MIF induced CXCR7-Akt-dependent phosphorylation of BCL-2 antagonist of cell death (BAD) both in vitro and in vivo. Consequentially, MIF failed to rescue Akt −/− platelets from thrombin-induced apoptosis when challenged ex vivo, also in prolonging platelet survival and in inducing BAD phosphorylation among Akt −/− mice in vivo. MIF reduced thrombus formation under arterial flow conditions in vitro and retarded thrombotic occlusion after FeCl 3 -induced arterial injury in vivo, an effect mediated through CXCR7. Conclusion: MIF interaction with CXCR7 modulates platelet survival and thrombotic potential both in vitro and in vivo and thus could regulate thrombosis and inflammation. (Circ Res. 2014;115:939-949.) (S.A.-R., J.B.). The online-only Data Supplement is available with this article at http://circres.ahajournals.org/lookup/suppl/
P latelets are multifunctional cells that play a critical role in wound healing, immune defense, and repair mechanisms at sites of vascular and tissue injury. [1] [2] [3] Platelets undergo apoptosis 4 either as part of a spontaneous senescence program or after activation. Stimulation of platelets with agonists like thrombin or collagen at sites of platelet accumulation induce apoptosis or apoptosis-like events, such as phosphatidylserine externalization, cell shrinkage, loss of mitochondrial transmembrane potential (∆ψm), or caspase-3 activation. 4, 5 However, mechanisms that protect platelets against apoptosis to confer survival and implications of this process are incompletely understood.
Platelets harbor a wide array of pro-and anti-inflammatory/angiogenic factors in their granular repertoire, 6 many of which could regulate vascular injury/inflammation, and which might also influence platelet survival. Recently, we described that platelets express both chemokine receptors CXCR4 and CXCR7 7, 8 and that surface expression of CXCR7 is significantly elevated in patients with acute coronary syndrome as compared with stable angina pectoris. 8 Platelet CXCR7 surface expression significantly correlates with levels of its ligand CXCL12 and with functional recovery after myocardial infarction. Moreover, CXCL12 induces differential cellular trafficking of CXCR4/CXCR7 through active involvement of Erk1/2 and cyclophilin A and rescues platelets from activation-induced apoptosis. 7 Macrophage migration inhibitory factor (MIF), a widely expressed and pleiotropic cytokine and a chemokine-like factor is a ligand for CXCR4, 9 induces monocyte migration and their November 7, 2014 differentiation into macrophages, which in turn modulates vascular inflammation. MIF is thus a pivotal regulator of atherogenesis and also plaque vulnerability. [10] [11] [12] MIF is associated with extensive lesion development, 12, 13 whereas blocking MIF or its genetic deletion reduces macrophage and T-cell content in atherosclerotic plaques and attenuates atheroprogression in ApoE −/− mice. 14 MIF promotes the proinflammatory functions of immune cells and is involved in the pathogenesis of sepsis, rheumatoid arthritis, inflammatory, and autoimmune diseases apart from atherosclerosis. [11] [12] [13] [14] [15] Because most of these diseases are ameliorated by either genetic deletion of Mif or MIF neutralization, anti-MIF therapies have raised significant clinical interest. MIF levels in plasma are enhanced in patients with acute myocardial infarction and associated with inflammatory markers C-reactive protein and IL-6 and correlate with cardiac necrosis marker troponin I release. Patients with acute coronary syndrome caused by plaque rupture show significantly higher plasma levels of MIF than patients with flow-limiting stenotic lesions. 16 Platelets have been characterized as a source of MIF, which when released on platelet activation can induce migration of monocytes along with SDF-1α/CXCL12. 17 However, the potential effect of MIF on platelets themselves remained elusive. MIF effects on target cells depending on cell type and functional context are executed through interaction with the receptors CXCR2, CXCR4, CD74, and CXCR7. Platelets are anucleated terminally differentiated cells with limited migratory activity under hemodynamic stress, but regulate hemostasis, inflammation, and regeneration, all of which can be potentially modulated by their relative survival or life span in circulation. 1, 4 In the present study, we evaluated the role of MIF on platelet survival and thrombotic potential.
Methods
A detailed account of materials and methods used in the study is provided in the Online Data Supplement.
Results

Differential Effects of MIF and CXCL12 on Translocation of CXCR4 and CXCR7
CXCL12 is a high-affinity ligand for CXCR4 and CXCR7. 18 Ligation of CXCR4 with CXCL12 results in enhanced surface translocation of CXCR7 on the platelets, which exerts a prosurvival effect. 7 MIF also binds to CXCR4 and triggers leukocyte chemotaxis. 9,10 Thus, we asked whether MIF could regulate the differential trafficking of CXCR4-CXCR7 and platelet survival as evidenced for CXCL12. 7 MIF, like CXCL12, induced internalization of CXCR4 ( Figure 1A and Online Figure I for control stainings), but did not induce CXCR7 externalization like CXCL12 ( Figure 1A ). Therefore, although both MIF and CXCL12 bind to CXCR4 and induce CXCR4 internalization, only CXCL12 leads to CXCR7 externalization, suggesting a ligand-specific CXCR4-mediated signaling in platelets. MIF and another CXCR7-specific ligand, that is, CXCL11, did not affect the CXCL12-induced CXCR4 internalization. However, they counteracted CXCL12-mediated externalization of CXCR7 (Online Figure II) . Moreover, MIF did not alter the activation status of platelets either when administered alone or in combination with platelet agonist (Online Figure  III) nor did it alter the formation of filopodia/lamellipodia on activation-induced shape change while adhering to fibrinogencoated surface (Online Figure IV) . CXCL12/CXCR4-ligation leads to Erk1/2 phosphorylation, an essential prerequisite for CXCL12/CXCR4-driven surface translocation of CXCR7. 7 However, MIF, in contrast to CXCL12, did not induce Erk1/2 phosphorylation, either in platelets ( Figure 1B ) or in primary T lymphocytes (Online Figure VA) . Thus, absence of MIF-induced Erk1/2 phosphorylation is part of the differential effect of ligandspecific CXCR4-dependent signaling in platelets accounting for the lack of CXCR7 surface translocation. However, like CXCL12, MIF could induce Erk1/2 phosphorylation in monocytes ( Figure 1B) .
MIF binds to the chemokine receptors CXCR2, CXCR4, and CXCR7. 9, [19] [20] [21] [22] Both CXCR2-CXCR4 can form functional complexes with the single-pass transmembrane-receptor CD74. 9 CD74 is essential for MIF-dependent Erk1/2 phosphorylation 19 after CXCR4 ligation. Although platelets express CXCR4 and CXCR7, both CXCR2 and CD74 were absent on the platelet surface ( Figure 1C ). Thus, lack of CD74 in platelets might be a determinant in defining the ligandspecific CXCR4-dependent signaling effects and translocation of CXCR7. Unlike platelets, monocytes expressing CD74 (Online Figure VB 
MIF Ligates CXCR4 and CXCR7 on Platelet Surface
We further verified MIF ligation to CXCR4-CXCR7 on platelets. MIF could be detected on the surface of untreated platelets possibly coming from an autocrine source, which was substantially (P<0.001) enhanced in platelets treated with rh-MIF ( Figure 2A ). Binding of rhMIF to the platelet surface was significantly inhibited in the presence of both anti-CXCR4 and anti-CXCR7 antibodies (P<0.001), suggesting receptor ligation. Further, platelets were incubated with rhMIF, and CXCR4-CXCR7/MIF interaction was analyzed by coimmunoprecipitation. We found that MIF coimmunoprecipitated with both CXCR4 and CXCR7, confirming a receptor-ligand interaction ( Figure 2B ). Immunofluorescence confocal microscopy also revealed that MIF colocalized with CXCR4 and CXCR7 on the platelet surface ( Figure 2C ). Moreover, CXCL11, another CXCR7-specific ligand, also showed significant (P<0.001) binding to the platelet surface ( Figure 2D ), confirming the specificity of the experimental approach.
CXCR7 Is the Predominant Receptor for Mediating Antiapoptotic Effects of MIF on Platelets
MIF promotes cell survival. 11, 21 Therefore, we asked whether MIF can modulate survival of platelets, as described recently for CXCL12. 7 Platelets were treated with MIF or CXCL11 for 30 minutes before thrombin-related peptide SFLLRN or BH3 mimetic ABT-737 was added to induce apoptosis. In the presence of MIF and CXCL11, thrombin-receptor activating pepetide and ABT-737-induced apoptosis in platelets was significantly (P<0.05) attenuated as evidenced by mitochondrial transmembrane potential (ΔΨm) loss (TMRE [tetramethylrhodamine, ethyl ester] fluorescence), change in annexin-V binding, and caspase-3 activation ( Figure 3A and 3B). Because MIF-dependent internalization of CXCR4 did not result in Erk1/2 activation due to the lack of CD74 and CXCR2 being absent on platelets, it was tempting to speculate that MIF might be executing its prosurvival effects through CXCR7. As predicted, in the presence of blocking anti-CXCR7 antibody (but not a respective control or blocking anti-CXCR4), MIF and CXCL11 could not antagonize activation-induced apoptosis ( Figure 3C ). These prosurvival effects of MIF as mediated through CXCR7 in platelets were further substantiated in cells where CXCR7 is either genetically deleted as in murine embryonic liver cells or is stably overexpressed as in Madin-Darby canine kidney cell transfectants ( Figure 3D and 3E). MIF could not rescue CXCR7 −/− murine embryonic liver cells from ABT-737-induced apoptosis unlike their CXCR7 +/+ counterparts ( Figure 3D ). Moreover, in Madin-Darby canine kidney cell lines stably transfected with CXCR7, MIF could rescue from starvation-induced apoptosis ( Figure 3E ). As an antiapoptotic factor, MIF reduced externalization of phosphytidylserine (deciphered by Annexin V binding), which is an eat-me signal. This could affect the phagocytic uptake of platelets by macrophages. As predicted, MIF reduced the phagocytic uptake of nonapoptotic (in presence of MIF) as compared with apoptotic (in absence of MIF) platelets by macrophages ( Figure 3F ). Because MIF rescued platelets from undergoing apoptosis, it did not necessitate their phagocytic uptake by macrophages.
MIF/CXCR7-Initiated Platelet Survival Is Mediated Through Akt-Dependent Phosphorylation of Proapoptotic BAD
To decipher the downstream signaling intermediates involved in MIF-induced platelet survival, we evaluated the effects of various pharmacological kinase inhibitors. In the presence of PI3K-(wortmannin) and Akt-inhibitor (SH-6), the antiapoptotic effects of MIF and CXCL11 ( Figure 4A ) were significantly reduced (P<0.05), an observation strongly suggesting the involvement of the PI3K-Akt pathway in MIF/CXCR7-dependent platelet survival. Further, the importance of Akt in prompting MIFinitiated platelet survival was also evidenced and exemplified in Akt −/− murine platelets. Unlike in wild type Akt +/+ platelets, neither MIF nor CXCL11 inhibited activation-induced apoptosis (TMRE fluorescence) in Akt −/− platelets ( Figure 4B ). This lack of the prosurvival effect among Akt −/− platelets was not because of a difference in the basal level of CXCR4/CXCR7 surface expression ( Figure 4C ) or their differential trafficking in response to CXCL12 and MIF, which was comparable to wild type.
We confirmed MIF-mediated induction of the PI3K-Akt pathway in platelets as reported previously 22 in other cells ( Figure 5A and 5B) comparable to that induced by CXCL12 and CXCL11 ( Figure 5A, left panel) . Moreover, both MIF and CXCL11 induced PI3K ( Figure 5A ) and Akt ( Figure 5B ) phosphorylation in platelets, which was substantially (P<0.01) reduced in presence of CXCR7 but not CXCR4-blocking antibody ( Figure 5A and 5B), confirming the initiation of the prosurvival PI3K-Aktsignaling cascade dowstream of CXCR7-MIF ligation.
Akt activation results in phosphorylation-mediated inactivation of proapoptotic BAD (BCL-2 antagonist of cell death), a BH3-only protein which regulates platelet apoptosis. 4, 23 Thus, we asked whether MIF inactivates (phosphorylates) BAD downstream of CXCR7 ligation. MIF induced BAD phosphorylation in a time-dependent manner ( Figure 5C, left) , which was inhibited in the presence of CXCR7 but not CXCR4blocking antibody (Figure 5C, right) . Similar results were obtained with CXCR7-ligand CXCL11 24 (Figure 5C and 5D) . MIF-and CXCL11-induced BAD-phosphorylation was significantly (P<0.05) abrogated in the presence of Akt inhibitor-SH-6 ( Figure 5C and 5D ). Evidently, BAD-phosphorylation among apoptotic platelets in response to MIF was also absent in Akt −/− murine platelets, whereas WT platelets showed BADphorsphorylation in response to MIF, which was abrogated by blocking CXCR7 and by Akt inhibition ( Figure 5E ).
MIF Attenuates Thrombus Formation Through CXCR7 Engagement
Platelet activation and enhanced phosphatidylserine surface exposure regulates thrombus formation. 25 Phosphatidylserine exposure is not only an indicator of apoptosis but also of platelet activation, leading to phospholipid scrambling at the plasma membrane. Because MIF exerts an antiapoptotic effect against activation-induced apoptosis and significantly reduces phosphatidylserine exposure ( Figure 3B ), we presumed that it might modulate thrombus formation. In the presence of MIF (200 ng/mL), platelets formed substantially smaller thrombi with a significantly (P<0.001) reduced thrombus surface coverage ( Figure 6A ). In the presence of blocking anti-CXCR7 or anti-CXCR4 antibody but not IgG control, the effect of MIF on thrombus formation was significantly (P<0.001) reduced. Immunostaining of thrombi revealed significantly higher TMRE and lower Annexin V signals in MIF-treated sets ( Figure 6A ). We further evaluated the thrombogenic potential of platelets from Mif −/− mice, which lack an endogenous source of MIF. Mif −/− mice showed enhanced thrombus formation as compared with Mif +/+ . Supplementation with rmMIF substantially reversed the effect ( Figure 6B ). 
MIF Prolongs Platelet Survival and Attenuates Thrombus Formation After Arterial Injury In Vivo
Prosurvival effects of MIF against platelet apoptosis in vitro were further substantiated in vivo after injection of recombinant MIF into Akt +/+ and Akt −/− mice. MIF injection significantly (P<0.05) promoted retention of labeled circulating platelets within a span of 5 days among WT but did not have any effect on Akt −/− mice with respect to control ( Figure 7A ). Moreover, MIF administration in vivo induced BAD-phosphorylation in circulating Akt +/+ but not Akt −/− mice platelets substantiating the Western blot data and even more so after ex vivo challenge with thrombin ( Figure 7A ). Phosphorylation-mediated inactivation of BAD in circulating platelets could contribute to prolonged survival under the influence of MIF. MIF administration in vivo also significantly reduced the thrombotic potential of platelets from Akt +/+ mice platelets as evaluated on day 5 ( Figure 7A ) in a dynamic flow chamber assay.
We further verified the antithrombotic potential of MIF in vivo by using intravital microscopy and FeCl 3 -induced arterial injury in mice. Time to arterial occlusion after FeCl 3 -induced injury of mesenteric arterioles in mice was significantly prolonged with occlusion time of ≥40 minutes under the influence Figure 7B ). Therefore, MIF exerted its antithrombotic effect through CXCR7 engagement after vessel injury.
Discussion
The major findings of the present study are the following: (i) MIF and CXCL12 differentially regulate the relative expression of their receptors CXCR4 and CXCR7 on the platelet surface. MIF can internalize CXCR4 like CXCL12, but fails to induce Erk1/2 phosphorylation-mediated surface translocation of CXCR7. (ii) MIF ligates CXCR7 and counteracts apoptosis in platelets through activation of the PI3K-Akt pathway causing phosphorylation of proapoptotic BAD and also relatively prolongs platelet survival in circulation. (iii) MIF limits phosphatidylserine exposure and consequentially regulates thrombus formation through CXCR7 involvement after arterial injury. Our findings establish CXCR7 as a hitherto unrecognized receptor for MIF on platelets involved in modulating platelet apoptosis (Figure 8 ) and imply a novel role for MIF in limiting thrombus formation.
Recently, Strüßmann et al deciphered platelets as a novel source of MIF and demonstrated the potential importance of platelet-derived MIF in governing monocyte migration and thus possibly vascular inflammation. 17 The potential effect of MIF on platelet function and survival is unknown. MIF ligates CXCR2, CXCR4, 9, 10, 19 and CD74, 19, 26 which forms a complex with CD44. 21, 27 Recently, we documented that CXCL12-CXCR7 might contribute to enhance the regenerative efficacy of platelets, 8 which can be substantially influenced by the survival of platelets at the site of action. Because CXCR7 is a vital receptor in modulating platelet survival and therefore has relevant clinical consequences, 8 we verified the potential effect of MIF in governing platelet survival possibly through CXCR7 (and CXCR4) as compared with a CXCR7-specific ligand, that is, CXCL11.
Presently, we describe that similar to CXCL12 and CXCL11, MIF protects platelets from activation and BH3 mimetic-induced apoptosis. Even though the prosurvival effects of CXCL12 and MIF are similar, we observed significant differences in the underlying mechanisms. Previously, the kinetics and pattern of CXCL12 and MIF release from platelets in response to agonists was addressed showing a distinctive difference 17 ; hereby, we provide convincing evidence that after release, both these chemokines could have a differential effect on the relative surface availability of their receptors on platelets, that is, CXCR4-CXCR7. Both MIF and CXCL12 are known ligands for CXCR4 9, 10, 19, 20 and induce receptor internalization in platelets (7 and Figure 1 herein) . Unexpectedly, in contrast to CXCL12, MIF did not stimulate Erk1/2 phosphorylation in platelets (like in T cells but unlike in monocytes) because of the absence of CD74 and failed in subsequent CXCR7 surface translocation.This suggests a ligand-specific (MIF versus CXCL12) effect on CXCR4-triggered signaling in platelets. Thus, a difference in spatial distribution of MIF and CXCL12 owing to different release kinetics 17 also translates to differential signaling mechanisms, possibly to govern distinct cellular functions which require in-depth characterization.
MIF can individually bind to CD74 or CXCR2/CXCR4 with high affinity, independent of the presence of the other receptor partner. MIF binding to CD74 results in activation of Erk1/2, also PI3K/Akt signaling, regulating cell proliferation and survival. [19] [20] [21] [22] Previously, MIF was identified to promote cell survival by activating the Akt pathway. 28, 29 In human rhabdomyosarcoma cell lines, which secrete MIF 20 but do not express CXCR2 and CD74 like platelets, MIF triggers phosphorylation of MAPK p42/44 and Akt, enhances adhesion to fibronectin and human umbilical vein endothelial cells (HUVECs), and promotes tumor vascularization. CXCR7 is the predominant receptor to mediate the prosurvival activity of CXCL12. 7 Presently, we found that MIF promotes platelet survival in circulation when administered in vivo and rescues platelets from apoptosis predominantly via CXCR7, like CXCL11. This data on platelet is further substantiated by Cxcr7 −/− embryonic cells where MIF could not exert its antiapoptotic effect against ABT-737-induced apoptosis. Moreover, MIF could rescue CXCR7 expressing Madin-Darby canine kidney cell transfectants from starvation-induced apoptosis. The MIF/CXCR7-dependent antiapoptotic effect was dependent on the PI3K-Akt-pathway as indicated by pharmacological inhibition of PI3K-Akt and the inability of MIF to rescue platelets from apoptosis or prolong circulating platelet survival in Akt −/− mice. Phosphorylation of the downstream target BAD by Akt was the final determinant in executing the prosurvival effects after MIF ligation of CXCR7 both in vitro and in vivo. One might contemplate on the functional relevance of these platelets in circulation, which show prolonged survival. Currently, we deciphered the relative thrombotic potential of platelets from Akt +/+ mice, which show prolonged platelet survival in circulation under the influence of MIF compared with Akt −/− mice, where MIF did not exert any significant effect. Interestingly, the thrombogenic activity of platelets from MIF-treated Akt +/+ mice was significantly reduced. It would be worthwhile investigating the regenerative capacity of these platelets in circulation, which show prolonged survival.
Because the antiapoptotic effect of the MIF/CXCR7 interaction involves an attenuation of prothrombotic phosphatidylserine exposure on the platelet surface, we hypothesized that MIF/ CXCR7 might also potentially regulate thrombus formation. Previously, we identified acid sphingomyelinase, involved in membrane scrambling and degranulation in regulating platelet secretion and initiation of procoagulant activity. Acid sphingomyelinase enhances activation-dependent degranulation and thrombin generation after phosphatidylserine exposure on platelets, resulting in enhanced arterial thrombus formation without affecting agonist-induced increases of cytosolic Ca 2+ and integrin α IIb β 3 activation or aggregation. 25 The clinical relevance of a dysregulation in phosphatidylserine exposure is exemplified in Scott syndrome, a bleeding disorder whereby the Ca 2+ -dependent phospholipid scrambling of platelets and other blood cells is impaired. 30 Externalization of phosphatidylserine is either dependent/independent of mitochondrial depolarization resulting from induction of apoptosis (as triggered by BH3-mimetic) or after platelet activation with convulxin/ thrombin and collagen/thrombin, glycoprotein VI stimulation, and PAR1-PAR4 activation. 30 Because MIF counterregulated not only activation-induced but also ABT-737-induced apoptosis in platelets, it appeared to be a potential candidate in modulating their thrombotic potential. Here we found that MIF attenuates thrombus formation both in vitro and after arterial injury in vivo through CXCR7 involvement. Moreover, MIF prolonged the initiation of platelet procoagulant activity denoted by the time to peak of thrombin generation in a thrombin generation assay using platelet-rich plasma by the calibrated automated thrombography method (data not shown). This is in keeping with the observed prolonged time to occlusion in injured arterioles as seen in MIF-treated mice with occlusion time of ≥40 minutes as compared with 10 minutes in control. MIF neither altered integrin activation (PAC-1 binding) by itself nor that induced by conventional platelet agonist like thrombin-receptor activating pepetide. This could bear promising clinical relevance in patients undergoing antiplatelet therapy against cardiovascular syndromes and cerebral ischemia. Continued debates regarding relative efficacy and dosage regimen of antiplatelet therapies warrants novel candidates. Agents that check thrombotic aspects without compromising the hemostatic and regenerative capacity of platelets are wanted, and MIF could potentially emerge as a relevant physiological candidate.
On the other hand, platelet-derived MIF released at the site of platelet activation/adhesion might foster platelet survival to ensure sustained platelet-dependent tissue regeneration and repair. Human platelets are estimated to harbor 3 femtogram of MIF/cell 17 and with the substantial number of circulating platelets might contribute significantly to plasma levels. MIF being a proinflammatory chemokine-like cytokine, this could significantly contribute to vascular inflammation. Previously, we reported elevated plasma levels of MIF in patients with acute coronary syndrome as compared with symptomatic coronary artery disease and healthy subjects, which was associated with other systemic inflammatory markers like C-reactive protein and IL-6 and correlated with troponin release. 16 Platelets having been acknowledged as a substantial source of MIF, these clinical observations need to be reevaluated to determine the contribution of platelet-derived MIF in these contexts. Nevertheless, MIF coming from a paracrine source at the site of vascular inflammation, injury, atherosclerotic lesions, or other circulating cells like monocytes and macrophages is enough to register the changes as deciphered here even in the absence of plateletderived MIF. Thus, irrespective of its origin, MIF can exert an autocrine/paracrine effect on platelets and thereby regulate platelet survival and thrombotic properties. Platelets being a readily available source of chemokines, cytokines, growth factors, which modulate platelet-inflammatory cell or platelet-endothelial interactions, their sustained survival might profoundly influence the duration and resolution of inflammatory processes, for example, onset and progression of atherosclerosis, plaque stability, and symptomatic coronary artery disease. Figure 8 . Schematic representation demonstrating that macrophage migration inhibitory factor (MIF) binds to CXCR4 and internalizes the receptor. However, because of the absence of the coreceptor CD74 on the platelet surface, MIF cannot transduce signals through CXCR4 to Erk1/2. MIF binds directly to the CXCR7 available on platelets and executes antiapoptotic effects. MIF induces downstream activation of PI3K-Akt and the phosphorylation-mediated inactivation of proapoptotic protein BAD to exert its prosurvival benefits.
